Chirag Parikh, M.D., Ph.D., F.A.C.P.
Associate Professor of Medicine

M.D., 1966: KEM Hospital, Bombay, India
Residency: Nassau University Medical Center, Stonybrook, NY
Fellowship: University of Colorado Health Sciences Center, Denver, CO
PhD in Clinical investigation, 2003, University of Colorado, Denver, CO

Email:chirag.parikh@yale.edu

The outcome of patients with acute renal failure remains unchanged in the last five decades despite tremendous advances in understanding the pathophysiology of acute renal failure at the cellular and molecular level. This issue is becoming increasingly recognized with an urgent need for patient oriented research to improve outcomes for this common condition.

My research focuses on determining optimal clinical strategies and identifying opportunities for improvement in the prevention, treatment, and outcome of acute renal failure. Specifically, I am studying the epidemiology of acute renal failure occurring with hematopoietic cell transplantation (bone marrow transplant). This human model of acute renal failure resembles the commonly seen renal dysfunction in the critically ill patients in the ICU. I am also investigating newer therapies for acute renal failure with compounds, such as Urodilatin, that are selective vasodilators. I am also involved with translating biomarkers such as urine IL-18, from bench to bedside, for early diagnosis of ARF. Delayed diagnosis of acute renal failure with traditional markers, like serum creatinine, is one of the main reasons for failure of interventional strategies in this setting.

In addition, I am building a consortium of transplant nephrologists to address medical, economic and psychosocial outcomes in kidney donors. The long-term outcomes in living kidney donors and the long term risks of donation are largely unknown. Our efforts will help us guide health policy and improve the informed consent process with living kidney donation.

PubMed Search for articles by faculty member

• Parikh CR, Ancukiewicz, Abraham E and Edelstein CL: Urine IL-18 is an Early Diagnostic Marker for ARF and Predicts Mortality in the ICU. In Press- J Am Soc Nephrol .
• Gibney, EM, Casebeer, AW, Schooley LM, Cunningham F, Grover F, Bell MR, McDonald GO, Shroyer L, Parikh, CR: Cardiovascular Medications are underutilized after Coronary Artery Bypass Grafting in Patients with Renal Dysfunction: A National Veterans Administration Study. In Press- Kidney International.
• Parikh, CR , McSweeney PA, Schrier RW: Acute Renal Failure is an Independent Predictor of Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Kidney Int 67: 1999-2005, 2005
• Parikh, CR, Schrier, RW, Storer, B, Diaconescu, R, Sorror, ML, Maris, MB, Maloney, DG, McSweeney, P, Storb, R, and Sandmaier, BM. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 45:502-509, 2005.
• Parikh, CR , Sandmaier, BM, Storb, RF, Blume, KG, Sahebi, F, Maloney, DG, Maris, MB, Nieto, Y, Edelstein, CL, Schrier, RW, and McSweeney, P. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 15:1868-1876, 2004.
• Parikh, CR , Jani, A, Melnikov, VY, Faubel, S, and Edelstein, CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43:405-414, 2004.